Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
Recent approvals of amyloid-targeting therapies have catalyzed an evolution in neurodegenerative disease investment and therapeutic development strategies.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
Appointed CEO 12 months ago, Anthony Costello wasted no time in orchestrating strategic change at Medidata. He talked to In Vivo about the art of the pivot and how to constantly push boundaries.
Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.
The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA, Darmstadt, Germany is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.
Biotech BPGbio applies causal AI to generate insights from samples from what the CEO says is one of the world's largest biobanks. With several promising late-stage programs, its platform seems to be yielding fruit.
With British Science Week upon us, how are UK life science firms faring, what’s the outlook for the future, and how can the environment be improved to better foster innovation – and make it pay?
Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.
